Grégoire Bellan

Grégoire Bellan

Auto-generated profile, based on publicly available information

Grégoire Bellan

SurgeCare, Paris, France

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
JHJulien Hédou
Julien Hédou
IMIvana Marić
Ivana Marić
GBGrégoire Bellan
Grégoire Bellan
JEJakob Einhaus
Jakob Einhaus
DGDyani K. Gaudillière
Dyani K. Gaudillière
BGBrice Gaudilliere
Brice Gaudilliere
Adoption of high-content omic technologies in clinical studies, coupled with computational methods, has yielded an abundance of candidate biomarkers. However, translating such findings into bona fide clinical biomarkers remains challenging. To facilitate this process, we introduce Stabl, a general machine learning method that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling. Evaluation of Stabl on synthetic datasets and five independent clinical studies demonstrates improved biomarker sparsity and reliability compared to commonly used sparsity-promoting regularization methods while maintaining predictive performance; it distills datasets containing 1,400–35,000 features down to 4–34 candidate biomarkers. Stabl extends to multi-omic integration tasks, enabling biological interpretation of complex predictive models, as it hones in on a shortlist of proteomic, metabolomic and cytometric events predicting labor onset, microbial biomarkers of pre-term birth and a pre-operative immune signature of post-surgical infections. Stabl is available at https://github.com/gregbellan/Stabl.

28 February 2023 in Research Square
Verified
Preprint
Open access
PDF file
JHJulien Hedou
Julien Hedou
IMIvana Maric
Ivana Maric
GBGrégoire Bellan
Grégoire Bellan
JEJakob Einhaus
Jakob Einhaus
DGDyani Gaudilliere
Dyani Gaudilliere
BGBrice Gaudilliere
Brice Gaudilliere
High-content omic technologies coupled with sparsity-promoting regularization methods (SRM) have transformed the biomarker discovery process. However, the translation of computational results into a clinical use-case scenario remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features included in multivariate models. We propose Stabl, a machine learning framework that unifies the biomarker discovery process with multivariate predictive modeling of clinical outcomes by selecting a sparse and reliable set of biomarkers. Evaluation of Stabl on synthetic datasets and four independent clinical studies demonstrates improved biomarker sparsity and reliability compared to commonly used SRMs at similar predictive performance. Stabl readily extends to double- and triple-omics integration tasks and identifies a sparser and more reliable set of biomarkers than those selected by state-of-the-art early- and late-fusion SRMs, thereby facilitating the biological interpretation and clinical translation of complex multi-omic predictive models. The complete package for Stabl is available online at https://github.com/gregbellan/Stabl.

8 July 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
SFStéphane Fattori
Stéphane Fattori
Laurent GorvelLaurent Gorvel
Laurent Gorvel
MRMarie-Sarah Rouviére
Marie-Sarah Rouviére
SGSamuel Granjeaud
Samuel Granjeaud
AAAmira Ben Amara
Amira Ben Amara
DODaniel Olive
Daniel Olive
Vγ9Vδ2 (TCRVγ9+ TCRVδ2+) T cells are promising immunotherapeutic targets with effective antitumor properties in both in vitro and preclinical models of triple-negative breast cancer (TNBC). However, no information about their potential role in the context of human TNBC progression and response to immunotherapy has been reported. One key reason for this is the scarcity of Vγ9Vδ2 T-cell infiltrates relative to their Vδ1 (TCRVδ1+) and αβCD8 (TCRαβ+ CD8αβ+) T-cell counterparts. We provide comprehensive single-cell profiling of Vγ9Vδ2 T cells from patients with TNBC, prior to and following PD-(L)1 blockade therapy. We report that baseline Vγ9Vδ2 T-cell infiltrate expressing a unique cytotoxic type I phenotype could be associated with improved survival in patients with TNBC. Vγ9Vδ2 T cells harboring characteristics of enhanced antitumor activity (KLRC1+) were further associated with improved response to PD-(L)1 blockade therapy in patients with TNBC. Vγ9Vδ2 T cells had low expression levels of T-cell exhaustion (PD-1LowTOXLow) and T-cell receptor signaling hallmarks compared with Vδ1 and αβCD8 T cells, along with skewed differentiation profiles toward early effector memory phenotypes, both before and after anti–PD-1 therapy in TNBC tumors. Consistently, we observed limited activity of anti–PD-1 on tumor-infiltrating Vγ9Vδ2 T cells. In vitro, the use of anti–butyrophilin-3A antibodies in addition to anti–PD-1 reinvigorated the cytotoxic type I functions of peripheral Vγ9Vδ2 T cells from patients with breast cancer. Together, these data provide a rationale for Vγ9Vδ2 T cell–based combination therapy in patients with TNBC.

11 February 2026 in Communications Medicine
Verified
Journal Article
Open access
PDF file
JGJonathan Garnier
Jonathan Garnier
GBGrégoire Bellan
Grégoire Bellan
APAnaïs Palen
Anaïs Palen
XDXavier Durand
Xavier Durand
JEJacques Ewald
Jacques Ewald
ACAnne-Sophie Chretien
Anne-Sophie Chretien
Background Postoperative pancreatic fistula (POPF) is the major driver of postoperative morbidity after pancreatoduodenectomy (PD) and a healthcare issue. In patients with pancreatic tumors the occurrence of POPF could lead to a complete failure of the oncologic strategy by delaying or annihilating the delivery of the indicated adjuvant chemotherapy. However, current preoperative prediction models lack precision. This study aimed to determine the ability of a high dimensional analysis of the patient’s peripheral immune system before PD to predict POPF. Methods Twenty-two patients in the prospective IMMUNOPANC trial (NCT03978702) underwent PD. Blood samples collected preoperatively were analyzed by combining single-cell mass cytometry and a sparse machine-learning pipeline, Stabl, to identify the most relevant POPF-predictive features. The logistic regression model output was evaluated using a five-fold cross-validation procedure. Results Eight (36%) patients experience POPF (grade B, n = 7; grade C, n = 1). The multivariable predictive model includes 11 features—six natural killer, three CD8+ T, and two CD4+ T lymphocyte cell clusters—revealing a preoperative POPF lymphocyte signature (Pancreatic Fistula Lymphocyte Signature, PFLS). The Stabl algorithm identifies a predictive model classifying POPF patients with high performance (area under the receiver operating characteristic curve=0.81, P = 2.04e-02). Conclusions In summary, preoperative circulating immune-cell composition can predict POPF in patients undergoing PD. The clinical application of the PFLS may enable the early identification of patients at high risk before pancreatic surgery, giving clinicians the opportunity to anticipate and mitigate POPF risk through tailored strategies in pre-, intra-, and post-operative settings.

1 October 2025
Verified
Other
Open access
PDF file
SFStéphane Fattori
Stéphane Fattori
Laurent GorvelLaurent Gorvel
Laurent Gorvel
MRMarie-Sarah Rouviére
Marie-Sarah Rouviére
SGSamuel Granjeaud
Samuel Granjeaud
AAAmira Ben Amara
Amira Ben Amara
DODaniel Olive
Daniel Olive
LM22 transcriptomic signatures do not selectively identify intratumoral γδ T cells.